Trials / Completed
CompletedNCT04552730
Nerve Growth Factor for the Treatment of Cornea Disease
Observational Study of Cenegermin-bkbj in the Treatment of Limbal Stem Cell Deficiency Associated With Neurotrophic Keratopathy
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 5 (actual)
- Sponsor
- Stanford University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To determine the efficacy and safety of nerve growth factor in the treatment of limbal stem cell deficiency (LSCD) associated with neurotrophic cornea.
Detailed description
This is a prospective open-label pilot study evaluating the role of cenegermin-bkbj for the treatment of LSCD with associated neurotrophic keratopathy. Patient diagnosed with LSCD with neurotrophic cornea who have failed conventional treatment such as artificial tears are enrolled in the study after a 2 week washout period. Patient are then treated with cenegermin-bkbj over an 8 week period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cenegermin-Bkbj | Topical Cenegermin-bkbj 6 times per day for 8 weeks. |
Timeline
- Start date
- 2020-10-14
- Primary completion
- 2021-05-04
- Completion
- 2021-05-04
- First posted
- 2020-09-17
- Last updated
- 2021-12-14
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04552730. Inclusion in this directory is not an endorsement.